2007•AtherosclerosisOpen access

Rosiglitazone produces a greater reduction in circulating platelet activity compared with gliclazide in patients with type 2 diabetes mellitus—An effect probably mediated by direct platelet PPARγ activation

Manish Khanolkar, R.H. Morris, Andrew W. Thomas, Hemanth Bolusani, Annette Roberts, John Geen, S.K. Jackson, Marc Evans

Open full text 46 citations

Abstract

This record does not include an abstract. Use the full-text link above if available.

About this research paper

What this paper is about

An abstract is not available in the OpenAlex record for this paper.

Why it matters

OpenAlex reports 46 citations for this work. Citation counts describe recorded attention and do not establish research quality.

Key contribution

A contribution statement is not available in the OpenAlex record.

Method / approach

Method details are not available in the OpenAlex metadata.

Main findings

Findings are not separately available in the OpenAlex metadata.

Limitations

Limitations are not available in the OpenAlex metadata.

Applications

Application details are not available in the OpenAlex metadata.

Key concepts: Gliclazide, Rosiglitazone, Platelet, Internal medicine, Metformin, Medicine, Oxidative stress, Endocrinology

Back to paper search Browse research topics Original source

Rosiglitazone produces a greater reduction in circulating platelet activity compared with gliclazide in patients with type 2 diabetes mellitus—An effect probably mediated by direct platelet PPARγ activation — Research Paper | ScholarLens